BLCO Bausch + Lomb Corporation

FDA Catalyst Company
17.18
-0.34  -2%
Previous Close 17.52
Open 17.72
52 Week Low 16.01
52 Week High 20.2
Market Cap $6,013,000,000
Shares 350,000,000
Float 35,000,000
Enterprise Value $7,986,649,517
Volume 1,130,507
Av. Daily Volume 670,517
Live cash est $88,666,444,222
Cash Burn N/A
No. Mths Cash 12
Insiders % 0.2
Total debt to equity 4.35
Earnings Date 01/01/2001
EPS 1.82
Rev guidance $10,459,000,000

Biotech Analyst Ratings

Analyst Action Rating Now PT Prior PT Now Last Updated
Cowen & Co. Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 30 day FREE TRIAL. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien. 05/11/2022

Latest News

  1. VAUGHAN, ON, May 16, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb" or the "Company"), a leading global eye health company dedicated to helping people see better to live better, has today filed its financial statements for the quarter ended March 31, 2022, in accordance with applicable Canadian securities laws. The Company intends to file its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2022 on or before June 20, 2022 (being the first business day that is 45 days from the date of effectiveness of Bausch + Lomb's Registration Statement on Form S-1, as amended, filed in connection with the Company's recent initial public offering) in compliance with the U.S. Securities and Exchange Commission…

    View Full Article
  2. VAUGHAN, ON, May 13, 2022 /PRNewswire/ -- Bausch + Lomb Corporation, (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the RBC Capital Markets Global Healthcare Conference on May 17, 2022, at 9:30 a.m. ET.

    A live webcast and audio archive of the conferences will be available on the Investor Relations page of the Bausch + Lomb website at: https://ir.bausch.com/investors/events-presentations.

    About Bausch + Lomb

    Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase…

    View Full Article
  3. Survey Reinforces Need for Innovative Therapies, Including Options Administered Through Suprachoroidal Space

    VAUGHAN, ON, May 12, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today released findings from a survey designed to gain an understanding of retina specialists' need for a new treatment option for patients with macular edema associated with noninfectious uveitis and the new drug delivery method in which treatment is administered via the suprachoroidal space. Approximately 85 percent of retina specialists surveyed considered drug delivery via suprachoroidal space as an option for patients with macular edema associated…

    View Full Article
  4. LAVAL, QC and VAUGHAN, ON, May 10, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb") and Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") today announced the closing of the initial public offering ("IPO") of Bausch + Lomb. A wholly owned subsidiary of Bausch Health (the "Selling Shareholder") sold 35,000,000 common shares at a public offering price of $18.00 per share for aggregate gross proceeds of $630 million, before deducting underwriting commissions and estimated offering expenses. The Selling Shareholder has granted the underwriters a 30-day option to purchase up to an additional 5,250,000 common shares of Bausch + Lomb to cover over-allotments, if any, at the initial public offering price, less discounts…

    View Full Article
  5. Bausch + Lomb Begins Trading under "BLCO" on NYSE and TSX

    Fully Integrated Eye Health Business Sets Its Sights On Helping the World See Better To Live Better

    VAUGHAN, ON, May 6, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (TSX:BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today launched as a publicly traded company focused on protecting and enhancing the gift of sight for millions of people around the world when it began trading under the "BLCO" symbol on the New York Stock Exchange and Toronto Stock Exchange.1

    Experience the interactive Multichannel News Release here:
    https://www.multivu.com/players/English/9046751-bausch-lomb-corporation-launches-as-publicly-traded-company/

    View Full Article
View All Bausch + Lomb Corporation News